. 2020 Oct 6;11:552988. doi: 10.3389/fimmu.2020.552988

Table 1.

Experimental details of Tol-DC transfer in animal transplant models.

Induction strategy	Phenotype of Tol-DC	Intervention	Transplanted model	Mechanism	Reference No.
DC pretreated with Cobalt Protoporphyrin (COPP)	HO-1^highMHC-II^lowCD40^lowCD80^lowCD86^low	Donor-derived Tol-DC(day -7, 5 × 10⁶ i.v.)	Allogeneic mouse cardiac	IFN-γ⁺ T cell↓, alloantibody production↓	(74)
DC infected with Recombinant human growth differentiation factor 15(GDF15) expression adenovirus	GDF15^highCD40^lowCD80^low	Autologous Tol-DC (day -7, 1 × 10⁶ i.v.) + Rapamycin (day 0-7,1mg/kg, i.p.)	Allogeneic mouse cardiac	T cell exhaustion↑, CD4⁺ FOXP3⁺Treg↑	(75)
DC treated with recombinant IL-35/Ebi3	MHC-II^lowCD86^lowCD80^low	Donor-derived Tol-DC (day -1, 1 × 10⁵ i.v.)	Allogeneic mouse cardiac	CD4⁺CD25⁺ FOXP3⁺Treg↑	(76)
DC cultured with urine induced pluripotent stem cells	CD11b^highCD11c^highMHC-II^lowCD86^lowCD80^low	Donor-derived TolDC (day -7, 1 × 10⁶ i.v.)	Allogeneic mouse cardiac	CD4⁺CD25⁺ FOXP3⁺Treg↑, cytotoxic T cell↓, TNF-α↓, IL-1β↓, IL-6↓	(77)
DC2.4 cells transduced with pAd5/F35-GFP-Jagged-1 viruses	Jagged-1^highMHC-II^intermediateCD80^intermediateCD86^intermediate	Exogenous Tol-DC (day -1, 5 × 10⁶ i.v.)+ anti-CD40L mAb (day 0, 2, 4 and 6, 0.25mg, i.p.)	Allogeneic mouse cardiac	CD4⁺CD25⁺ FOXP3⁺Treg↑, TGF-β↑, IFN-γ↓	(78)
DC infected with Relb shRNA expressing lentivirus, activated by LPS	Relb^lowMHC-II^lowCD86^lowCD80^lowCD83^low	Donor-derived Tol-DC (day -7, 5 × 10⁶ i.v.)	Allogeneic mouse cardiac	CD4⁺CD25⁺ FOXP3⁺Treg↑	(57)
DC pretreated with LF 15-0195	MHC-II^lowCD86^lowCD40^low	Exogenous Tol-DC (day -7, 5 × 10⁶ i.v.)	Allogeneic mouse cardiac	CD4⁺CD25⁺CTLA4⁺T cell↑, CD4⁺CD25⁺ FOXP3⁺Treg↑	(56)
DC treated with 0.1ng/ml GM-CSF	CD11c^highMHC-II^lowCD80^lowCD86^low	Autologous Tol-DC (day -1, 1 × 10⁶ i.v.) + anti-CD3 Ab (day -1, 300mg, i.v.)	Allogeneic mouse islet	T cell activation↓, alloantibody production↓, CD4⁺ FOXP3⁺Tregs↑	(79)
DCs treated with IL-10	MHC-II^lowCD40^lowCD86^lowCD205^lowIL-12p70^lowTNF-α^lowIL-6^lowIL-10^high	Autologous Tol-DC (day -1, 2 × 10⁶ i.v.)	Xenogeneic (rat-mouse) islet	Graft-infiltrating CD8⁺CD28^- and CD8⁺PD1⁺ suppressor T cell↑	(80)
DCs conditioned with TGF-β, activated by LPS	MHC-II^intermediateCD80^lowCD86^lowIL-12p70^low	Donor-derived Tol-DC (day 0, 5× 10⁵ i.v.)	Syngeneic mouse islet	FOXP3⁺Treg ↑	(81)
DCs conditioned with TNF-α and α1-Antitrypsin	MHC-II^lowCD86^lowCD80^lowIL-6^lowIL-12^lowIL-10^high	Autologous Tol-DC (day 0, 2 × 10⁶ i.v.)	Allogeneic rat kidney	FOXP3⁺Treg↑, TGF-β↑, IL-6↓, IFN-γ↓	(82)
DCs treated with 0.4ng/ml GM-CSF	CD11c^highMHC-II^lowCD80^lowCD86^low	Autologous Tol-DC (day -1, 1 × 10⁶ i.v.) + anti-CD3Abs (day −1, 1, 3, 5 and 7, 1mg, i.p.)	Syngeneic mouse skin	CD8⁺ FOXP3⁺Treg↑	(83)
DC cotransfected with plasmids encoding EGFP-hTGF-β1 and EGFP-hFasL	TGF-β^highFas-L^highCD85^lowCD80^low	Exogenous Tol-DC (day -5, 2× 10⁶ i.v.)	Allogeneic rat liver	IL-10↑, IL-1↓, IL-12↓	(84)
DC treated by GM-CSF,IL-10 and FLT3L	MHC-II^lowCD86^lowCD40^lowCD80^low	Donor-derived Tol-DC (day -7, 2× 10⁶ i.v.)+Penicillin (day 0, 500u/10g, subcutaneous)	Allogeneic rat kidney	IL-2↓, IFN-γ↓, IL-4↑, IL-10↑, CD4⁺CD25⁺ FOXP3⁺Treg↑	(85)
DCs stimulated by VitD3 and IL-10	CD14^highMHC-II^lowCD86^lowCD83^lowCD80^lowPD-L1^high	Donor-derived Tol-DC (day -7 and 3, 5-10× 10⁶ i.v.)+CTLA4 Ig (day -7 and -4, 12.5 mg/kg, day −1, 0, 2, 4, 7 and 10, 20mg/kg i.v.) + Tapered rapamycin maintenance	Allogeneic monkey kidney	CD4⁺CD95⁺Tmem↓, CD8⁺CD95⁺Tmem↓ CTLA4 and PD-1 expressed on Tmem↑	(86)
DCs stimulated by VitD3 and IL-10	CD14^highMHC-II^lowCD86^lowCD83^lowCD80^lowPD-L1^high	Donor-derived Tol-DC (day -7 and 3, 5-10× 10⁶ i.v.)+CTLA4 Ig (day -7 and -4, 12.5 mg/kg, day −1, 0, 2, 4, 7 and 10, 20mg/kg i.v.) + Tapered rapamycin maintenance	Allogeneic monkey kidney	Donor-specific Eomes^lowCTLA4^highCD8⁺ central Tmem↑	(87)
DCs stimulated by VitD3 and IL-10	CD14^highMHC-II^lowCD86^lowCD83^lowCD80^lowPD-L1^high	Donor-derived Tol-DC (day -7 and 3, 5-10× 10⁶ i.v.)+CTLA4 Ig (day -7 and -4, 12.5 mg/kg, day −1, 0, 2, 4, 7 and 10, 20mg/kg i.v.) + Tapered rapamycin maintenance	Allogeneic monkey kidney	Donor-specific Eomes^lowCTLA4^highCD8+ T cell↑, IL-17↓	(88)
DCs stimulated by VitD3 and IL-10	CD14^highMHC-II^lowCD86^lowCD83^lowCD80^low	Donor-derived Tol-DC (day -7 and 3, 5-10× 10⁶ i.v.)+CTLA4 Ig (day -7 and -4, 12.5 mg/kg, day −1, 0, 2, 4, 7 and 10, 20mg/kg i.v.) + Tapered rapamycin maintenance	Allogeneic monkey kidney	Donor-Specific CD4⁺CTLA4^high T Cell proliferation	(89)